Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00347438 · ClinicalTrials.gov registry record · Phase 2
Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00347438 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 18 participants.
The verdict
NCT00347438, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of capecitabine before surgery. The study will also help gain more information about the effects of the capecitabine on physical and emotional well-being and how well the participants on capecitabine follow the study drug plan.
Interventions
- DRUG Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00347438
The ClinicalTrials.gov registry entry for NCT00347438 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Capecitabine is the first listed.
NCT00347438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00347438 about?
NCT00347438 is a clinical study titled "Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer". The purpose of this study is to assess the safety and effectiveness of capecitabine before surgery. The study will also help gain more information about the effects of the capecitabine on physical and emotional well-being and how well the participants on capecitabine follow the study drug plan.
What is the current status of trial NCT00347438?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2006-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00347438?
The interventions under investigation include: Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00347438?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.